Trial Profile

REsPonse to Interferon-Alpha in InterfeRon-beta Neutralizing Antibody Positive Multiple Sclerosis Patients.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 08 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Interferon alpha (Primary) ; Interferon beta-1a; Interferon beta-1b
Indications Multiple sclerosis
Focus Biomarker; Pharmacodynamics
Acronyms REPAIR

Most Recent Events

16 Jan 2013 Only treatment table updated, ex-Vans.
08 Aug 2011 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
07 Jun 2011 European Clinical trials database reports 7 Jun 2011 as global end of the trial

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com